Xuan Hou
Yingjun Wei
Yongfeng Wang1- 1Gansu Medical College, Pingliang, Gansu, China
- 2Gansu University of Chinese Medicine, Lanzhou, Gansu, China
Insomnia, a prevalent sleep disorder, poses significant threats to both physical and mental health. Traditional studies suggest multiple factors are associated with insomnia, yet the causal direction often remains unclear and susceptible to confounding biases. Mendelian randomization, a cutting-edge method leveraging genetic instrumental variables for causal inference, effectively overcomes these limitations by providing high-quality evidence to clarify causal relationships between insomnia and various diseases. This review systematically integrates 105 recent Mendelian randomization studies on insomnia. Evidence indicates that insomnia exerts clear causal effects on multiple diseases, though the strength of these associations and the robustness of evidence vary by disease type. Insomnia is a robust risk factor for coronary heart disease, anxiety-depressive disorders, type 2 diabetes, and chronic pain. Causal relationships with osteoarthritis and lung cancer are also supported, though effect sizes are relatively small. Conversely, associations with Alzheimer’s disease and schizophrenia remain unconfirmed. The studies establish a dominant causal direction from “insomnia → disease,” effectively correcting potential reverse causality bias in observational research. These findings reposition insomnia from a common symptom to a key modifiable cause of a range of psychosomatic disorders. Causal inferences grounded in genetic evidence provide a robust scientific foundation for early identification of high-risk populations, precision prevention targeting insomnia, and cross-system comorbid management.
1 Introduction
Insomnia is a common clinical sleep disorder characterized by difficulty falling asleep, frequent awakenings during sleep, and difficulty returning to sleep after waking. Approximately 16.2% of adults worldwide experience insomnia to varying degrees, with nearly half of patients having a disease duration of ≥10 years (1). During the COVID-19 pandemic, global insomnia prevalence significantly increased (2), with 10% of recovered patients continuing to experience sleep disturbances (3). Chronic insomnia impairs neuroplasticity, manifesting as reduced synaptic density in the prefrontal cortex and decreased hippocampal neurogenesis (4, 5), while activating the stress-immune axis and elevating risks of depression and anxiety (6). Current first-line treatments include medication and cognitive behavioral therapy for insomnia (CBT-I). However, CBT-I coverage in primary care settings remains below 15% (7, 8), while benzodiazepine dependence rates reach 28–42% (9). Insomnia highly co-occurs with chronic conditions like depression, diabetes, and hypertension (10). However, randomized controlled trials (RCTs) face <5% applicability due to ethical constraints, while observational studies exhibit >30% causal reversal bias (11). Mendelian randomization (MR) leverages the random allocation property of genetic variants to simulate RCTs and reduce confounding (12, 13).
Mendelian randomization (MR) represents a novel research methodology for investigating causal relationships between exposure factors and outcomes. Grounded in Mendelian inheritance laws, MR employs genetic variants associated with risk factors as instrumental variables. These instruments must satisfy three core assumptions: (1) Strong correlation with the exposure factor (r2 > 0.01); (2) Independent of confounding factors; (3) Influencing the outcome solely through the exposure factor. It detects and explores associations between risk factors and diseases, mitigating the effects of confounding and reverse causality. By simulating randomized clinical trials through the principle of randomly assigned genetic variation, it provides insights into risk factors and drug targets to prioritize clinical trial investigations (14, 15).
The studies included in this review primarily employed inverse variance weighting (IVW) as the main method for estimating causal effects, as it provides the most precise estimates when all instrumental variables used are valid. To assess potential multi-effect bias, we focused on whether studies reported the following sensitivity analyses: MR-Egger regression (to detect and correct directional multi-effect bias), where an intercept p > 0.05 typically indicates negligible multi-effect bias; and weighted median method (which provides consistent estimates even if some instrumental variables are ineffective). We judged the reliability of evidence based on the following criteria: (1)Primary analysis method (IVW) p < 0.05; (2) Instrument strength assessed via F > 10 to mitigate weak instrument bias; (3) Sensitivity analysis results consistent with primary analysis direction and showing no significant heteroscedasticity (MR-Egger intercept p > 0.05). Results meeting all criteria were deemed robust causal evidence.
2 Search strategy
The literature search, screening, and data extraction process for this study strictly adhered to the guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. We systematically searched three Chinese databases—China National Knowledge Infrastructure (CNKI), VIP, and Wanfang Data—along with two English databases, PubMed and Springer Nature Link. The search period spanned from each database’s inception to December 31, 2024. The search strategy combined subject headings with free-text terms. The Chinese search query was “(Insomnia) AND (Mendelian Randomization Analysis OR MR),” The English search query, using PubMed as an example, was: ((“Insomnia”[Mesh]) OR (Insomnia[Title/Abstract])) AND ((“Mendelian Randomization”[Mesh]) OR (“Mendelian Randomization Analysis”[Mesh]) OR (MR[Title/Abstract]) OR (“Mendelian Randomization”[Title/Abstract])).
Inclusion and exclusion criteria were as follows: (1) Inclusion criteria: ① Study type was Mendelian randomization analysis; ② Insomnia was used as either the exposure or outcome variable; ③ Full-text Chinese or English articles were available. (2) Exclusion criteria: ① Duplicate publications; ② Inaccessible full-text articles; ③ Non-Chinese or non-English language; ④ Repeated analyses based on the same dataset; ⑤ Significant methodological flaws.
Literature screening and data extraction were performed independently by two researchers. First, retrieved articles were imported into reference management software for deduplication. Subsequently, researchers independently screened remaining articles based on titles/abstracts and full texts. Any discrepancies during screening were resolved through discussion, with arbitration by a third senior researcher when necessary. Ultimately, 105 articles were included in the analysis. The detailed process is illustrated in the PRISMA flow diagram (Figure 1).
Figure 1. Retrieval strategy and research process diagram.
To systematically assess the methodological quality of included studies, we employed the Newcastle-Ottawa Scale modified for Mendelian randomization studies (NOS-MR) for independent evaluation. This assessment primarily covered four core dimensions: strength of instrumental variables (e.g., reporting validity evidence such as F-statistic > 10), application of core MR methods (e.g., correct use of inverse variance weighting), sensitivity analysis and multi-effect testing (e.g., adequate use of MR-Egger and weighted median methods), and heterogeneity testing and robustness of results. Study quality was categorized as high (7–8 points), moderate (5–6 points), or low (≤4 points) based on total scores, with specific criteria detailed in Table 1 footnotes. The assessment revealed that the overall quality of the included studies was above average, with most scores ranging between 5 and 8 points (Table 1). This indicates relatively adequate methodological reporting and robust core findings. Data extraction was conducted concurrently, capturing information including study characteristics, definitions of exposure and outcomes, details of instrumental variables, types of MR analysis, and primary results. This information was systematically compiled in Table 1 for subsequent analysis.
Table 1. Characteristics, main findings, and methodological quality of included Mendelian randomization studies on insomnia and various diseases.
3 The relationship between cardiovascular diseases and insomnia
An increasing number of epidemiological and genetic studies have confirmed a clear causal association between insomnia and various cardiovascular diseases (CVDs), a relationship that may be partially mediated by factors such as body mass index (BMI) and smoking behavior (16). Mendelian randomization (MR) studies, utilizing genetic instrumental variables, provide strong evidence for the potential causal link between the two. Among these, the association between insomnia and coronary heart disease (CHD) is most conclusive. Large-scale MR analyses demonstrate that genetically predicted insomnia significantly increases CHD risk (see Table 1 for details) (17) Zhang X et al.’s (18)MR study further validated insomnia’s causal role as an independent risk factor for multiple CVDs, with its effects remaining robust despite significant confounding by age, underlying diseases, and other factors. Some researchers (19) employed MR analysis to focus on specific CVD subtypes, revealing that genetic susceptibility to insomnia is significantly associated with an increased risk of atrial fibrillation (AF) onset (p < 0.006). Additional observational studies further confirmed that among individuals with various sleep disorders, those with insomnia symptoms exhibited the highest risk of acute myocardial infarction (AMI) (20), reinforcing the close association between insomnia and CVDs.
The pathophysiological mechanism primarily revolves around the core concept of “hyperarousal.” Insomnia leads to sustained activation of the sympathetic nervous system and the hypothalamic–pituitary–adrenal (HPA) axis, triggering dysregulation in catecholamine and cortisol secretion. This results in accelerated heart rate, elevated blood pressure, and vascular endothelial injury, directly promoting atherosclerosis (21–25). Concurrently, insomnia-related neuroendocrine dysregulation (e.g., decreased leptin, elevated ghrelin) disrupts energy metabolism, increasing obesity risk. This indirectly damages cardiovascular health through insulin resistance and chronic inflammation, forming a vicious cycle of “insomnia-obesity-CVD” (26). Genetic studies have also revealed that certain gene loci regulating circadian rhythms and inflammation are associated with both insomnia and CVD susceptibility, suggesting a shared genetic basis (27).
Current MR evidence indicates that the causal impact of insomnia on CVD exhibits variability. Its risk effects on CHD and AF appear relatively robust. However, for specific subtypes such as AMI, MR evidence remains insufficient, and observational studies may overestimate the association. Future research should validate these relationships in larger samples and further elucidate the specific contributions of mediating factors like BMI and inflammation.
4 Metabolic diseases and insomnia
The bidirectional interaction between insomnia and metabolic disorders (such as type 2 diabetes, obesity, and dyslipidemia) has been validated through multidimensional epidemiological, genetic, and mechanistic studies. Among these, MR studies leverage the natural randomness of genetic markers to effectively circumvent confounding biases and reverse causality issues, further clarifying the causal direction, effect magnitude, and core mediating mechanisms between the two (see Table 1 for details).
Robust evidence indicates that genetically predicted insomnia is a causal risk factor for type 2 diabetes and worsening glycemic control (elevated HbA1c) (28, 29). The underlying mechanisms involve cortisol rhythm disruption induced by insomnia, chronic low-grade inflammation (e.g., elevated IL-6 and CRP), and the resulting decline in insulin sensitivity (30, 31). Similarly, MR studies support a unidirectional causal effect of insomnia on increased body mass index, with no established reverse pathway (32). This likely occurs through altered appetite-regulating hormones (reduced leptin, elevated ghrelin) promoting increased caloric intake, synergizing with inflammatory factors to enhance fat accumulation (33, 34). Regarding dyslipidemia, insomnia may indirectly elevate risk by activating the HPA axis, altering dietary preferences (e.g., increased high-fat food intake), and exacerbating behaviors like smoking and alcohol consumption (35–40).
The causal relationship between insomnia and T2D/obesity is strongly supported by MR evidence, though effect sizes remain generally modest (OR typically ranging from 1.1 to 1.3). The association between insomnia and dyslipidemia is largely indirect, with weaker MR evidence. Given that most current studies are based on European populations, caution is warranted when extrapolating these findings.
Based on this evidence, a “sleep-metabolism” co-management strategy can be developed: - Incorporate sleep assessment (e.g., Pittsburgh Sleep Quality Index, PSQI) into management of high-risk populations for metabolic diseases. Monitor BMI, HbA1c, and inflammatory markers (IL-6, CRP) every 6–12 months in insomnia patients (41). For T2DM patients with insomnia, prioritize SGLT2 inhibitors (e.g., dapagliflozin) due to their ability to regulate plasma Ap4A, thereby simultaneously improving metabolism and sleep (42); For obesity-related insomnia, employ cognitive behavioral therapy for insomnia (CBT-I) combined with low-dose IL-6 receptor antagonists (e.g., tocilizumab) to disrupt inflammation-mediated vicious cycles (43); For dyslipidemia-related indirect pathways, intensify low-fat dietary interventions (≤30% daily caloric intake from fat) and smoking cessation/alcohol restriction in insomnia patients to reduce overlapping common risk factors (44–46).
5 Musculoskeletal disorders and insomnia
MR studies suggest that insomnia may be an underlying risk factor for specific musculoskeletal disorders. Evidence indicates a causal association between genetically predicted insomnia and increased risk of osteoarthritis and low back pain (47, 48). However, no direct causal link has been established between insomnia and rheumatoid arthritis; nonetheless, insomnia may create a susceptible environment for joint inflammation by elevating systemic inflammatory markers such as C-reactive protein (CRP) (49).
Preliminary MR evidence supports an association between insomnia and musculoskeletal pain (particularly osteoarthritis), though the effect size is small. Evidence for a direct genetic causal relationship between insomnia and rheumatoid arthritis or bone mineral density is insufficient or negative.
Its potential mechanisms are closely linked to chronic inflammation. Insomnia significantly upregulates pro-inflammatory cytokines like IL-6 and TNF-α (50), which not only suppress osteoblast activity and affect bone density but also serve as key drivers of synovial inflammation and cartilage degradation in rheumatoid arthritis and osteoarthritis (51–54). Although current research has preliminarily revealed the association patterns and partial mechanisms between sleep and skeletal health, critical gaps remain: existing evidence predominantly focuses on macro-level correlations and classical inflammatory pathways, while the specific molecular mechanisms by which insomnia regulates bone metabolism remain unclear. Future studies could integrate single-cell RNA sequencing to analyze differentially expressed genes in osteoblasts/osteoclasts under insomnia conditions (e.g., RUNX2, RANKL); Concurrently, epigenetic studies should explore the role of DNA methylation (e.g., NR3C1 gene methylation) in insomnia’s impact on skeletal health. Deepening our understanding of core pathways through these cutting-edge technologies will provide theoretical foundations for developing targeted clinical interventions and disease prevention strategies along the sleep-bone health axis.
6 Pain disorders and insomnia
Pain is an unpleasant subjective emotional experience associated with tissue damage or the threat of tissue damage (55). Sleep and pain exhibit a close and complex bidirectional interaction. MRI studies confirm a significant bidirectional causal relationship between insomnia and various chronic pain conditions (e.g., widespread pain, headache, back pain), though the effects are asymmetric: insomnia’s impact on pain is stronger than pain’s reverse effect on insomnia (56, 57). Furthermore, insomnia has been identified as a distinct risk factor for migraine (58).
The neurobiological basis of this interaction involves multiple systems. Insomnia can lead to reduced endogenous opioid system function, decreased serotonin levels, and cortisol dysregulation caused by HPA axis disruption, collectively resulting in lowered pain thresholds and pain sensitization (59–61). Clinical evidence indicates that improving insomnia in patients with knee osteoarthritis is associated with concurrent enhancements in physical function, reduced knee pain, and diminished IL-6 responses to experimental pain stimuli (62), suggesting that sleep improvement may alleviate chronic pain by regulating inflammatory mediators.
Regarding therapeutic interventions, cannabinoids have been demonstrated to improve sleep through analgesic effects (63). non-benzodiazepine hypnotics (e.g., zopiclone) improve sleep without affecting pain, whereas benzodiazepines (e.g., triazolam) improve both. This difference may relate to the selective action of non-benzodiazepines on sleep-promoting neural regions (64, 65). Additionally, melatonin demonstrates clear efficacy in improving both sleep and pain (66).
In summary, the complex interactions within the sleep-pain axis offer a multi-target approach for clinical treatment. However, the specific mechanisms involving inflammatory mediators like IL-6, as well as the clinical translational value of interventions with low-level evidence, require further validation through in-depth research.
7 Relationship between mental disorders and insomnia
The high co-occurrence of insomnia with mental disorders such as depression and anxiety has been confirmed by extensive clinical research—the incidence of anxiety/depression symptoms among insomnia patients is significantly higher than in healthy populations, and the two conditions often mutually exacerbate each other, forming a clinical negative feedback loop of “insomnia-mental disorder” (67–69). MR studies have elucidated this complex causal network. The most compelling evidence indicates a strong bidirectional causal relationship between insomnia and anxiety disorders, where each condition exacerbates the other, creating a vicious cycle (70). Insomnia also constitutes a clear risk factor for major depressive disorder (71). Within the broader spectrum of psychiatric disorders, MR analysis indicates that insomnia increases the risk of developing attention-deficit/hyperactivity disorder and bipolar disorder, but no significant genetic causal association was found with autism spectrum disorder or schizophrenia (72). Reverse causality analysis similarly largely ruled out these psychiatric disorders as primary causes of insomnia.
The biological mechanisms underlying this comorbidity may involve shared disturbances in neuroendocrine and immune pathways, including HPA axis dysregulation, monoaminergic neurotransmitter imbalance, and neuroinflammatory responses mediated by immune mediators such as IL-6 and TNF-α (73). Regarding the molecular mechanisms underlying their comorbidity, studies suggest the PI3K-AKT pathway is a core inflammation-related pathway linking insomnia and depression (74). These findings provide evidence for early identification of psychiatric disorders while laying a theoretical foundation for subsequent targeted pathway drug development and clinical intervention strategies.
8 Relationship between central nervous system disorders and insomnia
Central nervous system disorders (stroke, Alzheimer’s disease, Parkinson’s disease, etc.) exhibit high comorbidity rates with insomnia. MRI studies suggest insomnia is a genetic risk factor for ischemic stroke, though its association with hemorrhagic stroke remains unclear (75, 76). Regarding neurodegenerative diseases, current MRI evidence does not support a direct causal relationship between insomnia and Alzheimer’s disease (77). Interestingly, daytime napping may reduce Alzheimer’s disease risk, warranting further validation. Metabolomics studies reveal shared serum metabolic dysregulation patterns between insomnia and Alzheimer’s disease/Parkinson’s disease (e.g., decreased acetylcholine, elevated propionylcholine), suggesting potential indirect co-morbidity pathways mediated by metabolism (78).
These findings not only provide evidence for risk stratification of central nervous system diseases (e.g., incorporating insomnia genetic susceptibility and serum acetylcarnitine levels into stroke/ Parkinson’s disease risk assessment), but also provide translational theoretical directions for synergistic interventions (e.g., targeting mitochondrial metabolism, optimizing daytime sleep strategies) and diagnostic biomarker screening (e.g., serum acetylcarnitine, propionylcarnitine). This holds significant clinical implications for improving the prognosis of patients with central nervous system diseases.
9 The relationship between cancer and insomnia
The potential association between insomnia and cancer has emerged as a research focus in epidemiology and oncology. Early observational studies, combined with MR research evidence, have identified insomnia as a potential risk factor for several cancers, including breast cancer, uterine cancer, prostate cancer, renal cancer, bladder cancer, and primary liver cancer (79, 80). The most well-established association is that insomnia increases the risk of lung cancer, with this effect partially mediated through promoting smoking and increasing body mass index (BMI) (81). Insomnia is also associated with an elevated risk of endometrioid ovarian cancer (82). However, MR analyses failed to establish a causal link between insomnia and bladder cancer, suggesting potential confounding factors in previous observational studies (83). Regarding the relationship between insomnia and thyroid cancer or breast cancer prognosis, existing MR evidence is limited or inconclusive, necessitating further research (84, 85).
Potential biological mechanisms may involve multiple pathways: insomnia disrupts circadian rhythms (e.g., by suppressing the tumor suppressor gene PER2), reduces melatonin secretion with anticancer properties, and activates pro-inflammatory pathways such as NF-κB, collectively creating a microenvironment conducive to tumor initiation and progression (86–89). Additional literature reports that melatonin can prevent tumor spread and worsened mortality by inhibiting tumor cell migration and reducing metastasis rates (90), providing a mechanistic reference for studies linking insomnia to cancer prognosis.
Integrating these MR studies on insomnia and tumors, clinical cancer treatment and management may consider measuring circadian rhythms of melatonin levels to explore dynamic sleep patterns across aging or post-cancer diagnosis. For high-risk populations like lung cancer, endometrioid epithelial ovarian cancer, or primary liver cancer patients, incorporating insomnia into risk assessment systems could prioritize sleep interventions to reduce disease incidence. For cancer patients, monitoring melatonin levels could optimize personalized treatment plans—such as exogenous melatonin supplementation to synergistically enhance antitumor efficacy and improve sleep quality—ultimately providing theoretical foundations and practical directions for precision cancer prevention and treatment.
10 Relationship between digestive system diseases and insomnia
The causal association between insomnia and digestive system diseases exhibits subtype specificity. Based on MR studies, only four disease categories—including duodenal ulcers and gastric ulcers—show significant positive correlations with insomnia, with varying effect sizes and mechanisms. Key findings are summarized in Table 1. In contrast, no significant associations were observed for inflammatory bowel disease or gastroesophageal reflux disease. Robust evidence indicates that insomnia is an independent causal risk factor for peptic ulcers (91, 92). Furthermore, insomnia significantly increases the risk of irritable bowel syndrome by disrupting the gut-brain axis, with gut microbiota dysbiosis playing a key mediating role (93, 94).
Dysbiosis of the gut microbiota serves as a central mediator linking insomnia to gastrointestinal disorders. Evidence indicates reduced gut microbial diversity in insomnia patients, with altered abundance of specific genera (e.g., Ruminococcus) correlated with insomnia risk (95, 96). These bacteria influence neurotransmitters (e.g., GABA) through their metabolites (e.g., short-chain fatty acids), thereby bidirectionally regulating sleep and gut function (97–99). It should be noted that current studies predominantly rely on fecal samples, and confounding factors such as diet may affect results (100–102).
These findings suggest that sleep assessments (e.g., Pittsburgh Sleep Quality Index, PSQI) should be integrated into screening protocols for high-risk populations with gastrointestinal diseases in clinical practice. Concurrently, modulating gut microbiota (e.g., through probiotic supplementation with Ruminococcus or Lactococcus species, or optimizing dietary fiber intake) may alleviate insomnia symptoms. This provides translational theoretical foundations and practical directions for the synergistic prevention and treatment of gastrointestinal diseases and insomnia.
11 Relationship between other diseases and insomnia
Multiple meta-regression studies have elucidated the association between insomnia and telomere length regulation, reproductive health, and immune dysfunction. Telomere length, as a marker of cellular aging, was previously hypothesized to have a causal relationship with sleep disorders (103). However, meta-regression analysis by He et al. (104) confirmed only a genetic correlation between the two, with significant gender differences: female insomnia patients exhibited more pronounced telomere shortening. Mechanistically, estrogen upregulates telomerase reverse transcriptase gene expression. Postmenopausal decline in estrogen levels may reduce this expression, accelerating telomere shortening and amplifying genetic susceptibility to insomnia (105, 106).
The causal association between insomnia in women of childbearing age and pregnancy outcomes was preliminarily confirmed by Yang et al.’s (107) two-sample Mendelian randomization study: genetic predisposition to insomnia exhibits a positive causal association with miscarriage risk. However, this study did not report causal estimates for insomnia and other perinatal outcomes. Based on existing evidence, clinicians may prioritize cognitive behavioral therapy for women with insomnia during preconception or early pregnancy, as it improves sleep efficiency (108–111) and may reduce miscarriage risk.
In the bidirectional regulation between the immune system and sleep, MRI studies have confirmed a causal relationship between plasma transforming growth factor-β-induced protein and preadrenal medullin with insomnia. This mechanism exacerbates insomnia by suppressing GABAergic neuronal activity and reducing slow-wave sleep duration (112).
In summary, insomnia’s cross-system impact network is jointly constituted by its genetic correlation with telomere length, causal linkages with reproductive health, and bidirectional regulation by immune cells/plasma factors. These findings suggest that clinically, monitoring relevant biomarkers can optimize insomnia risk stratification. Concurrently, behavioral interventions and targeted drug development provide evidence for the synergistic prevention and treatment of insomnia and related disorders.
12 Discussion
This review synthesizes 105 MR studies, demonstrating that the genetic risk of insomnia significantly increases the probability of developing over 30 chronic diseases across more than 12 major systems. Bidirectional MR analysis confirmed the primary causal direction as “insomnia → disease,” thereby clarifying over 30% of reverse causality bias observed in observational studies. Notably, causal associations between insomnia and Alzheimer’s disease, schizophrenia, autism spectrum disorder, bladder cancer, and telomere shortening were refuted by MR evidence, highlighting MR’s corrective value in etiological inference.
Integrating 105 Mendelian randomization studies reveals that genetic susceptibility to insomnia significantly elevates the probability of developing multisystem diseases across cardiovascular, metabolic, musculoskeletal, pain, psychiatric, digestive, oncological, and reproductive systems. Bidirectional MR analysis further confirms the primary causal direction as “insomnia → disease.” Notably, associations between insomnia and Alzheimer’s disease, schizophrenia, autism spectrum disorder, bladder cancer, and telomere shortening were refuted, suggesting prior findings may stem from residual confounding or reverse causation. Further multi-omics evidence converges insomnia’s cross-system pathogenic pathways onto the “hyperarousal-metabolism-inflammation” axis, forming a molecular hub for multi-disease co-occurrence.
However, the strength of existing evidence exhibits significant variation. Causal relationships between insomnia and coronary heart disease, anxiety/depression, type 2 diabetes, lung cancer, and chronic pain are supported by relatively robust MR evidence. In contrast, associations between insomnia and certain cancer subtypes, musculoskeletal disorders (excluding osteoarthritis), and gastrointestinal diseases (excluding peptic ulcers) are based on preliminary or limited evidence, requiring larger-scale studies for confirmation. Additional omics evidence converges the cross-system pathogenic pathways of insomnia onto the “hyperarousal-metabolism-inflammation” axis. Based on this, clinical consideration should be given to implementing sleep screening for high-risk populations. Interventions should center on cognitive behavioral therapy, with complementary therapies targeting specific pathways (e.g., melatonin supplementation, anti-inflammatory approaches) explored.
Evidence included in this review has limitations. First, dominant GWAS data originate from European populations, limiting the universality of conclusions. Second, insomnia definitions rely heavily on subjective reports, lacking objective measurement. Finally, current MR methods lack sufficient power for analyzing complex mediators like gut microbiota. Future efforts should establish multi-ethnic cohort studies combining objective sleep monitoring with multi-omics technologies, apply more sophisticated multivariate MR models, and validate potential intervention targets through randomized controlled trials to advance precision sleep medicine.
In summary, MR evidence redefines insomnia from a “comorbid symptom” to a “modifiable etiology.” Early identification and disruption of the “hyperarousal-inflammation” vicious cycle hold promise for reducing the overall burden of multiple chronic diseases.
Author contributions
XH: Writing – original draft, Writing – review & editing. YWe: Writing – original draft, Writing – review & editing. YWa: Writing – original draft, Writing – review & editing. LW: Writing – original draft.
Funding
The author(s) declared that financial support was received for this work and/or its publication. This work was supported by Special Project of the Science and Technology Talent Plan of Pingliang Science and Technology Bureau (PL-STK-2024A-030); General Project of Gansu Medical College (GY-2023FZZ07); Gansu Province University Faculty Innovation Fund Project (2026A-259).
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that Generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Benjafield, AV, Sert Kuniyoshi, FH, Malhotra, A, Martin, JL, Morin, CM, Maurer, LF, et al. Estimation of the global prevalence and burden of insomnia: a systematic literature review-based analysis. Sleep Med Rev. (2025) 82:102121. doi: 10.1016/j.smrv.2025.102121
2. Jahrami, H, BaHammam, AS, Bragazzi, NL, Saif, Z, Faris, M, and Vitiello, MV. Sleep problems during the COVID-19 pandemic by population: a systematic review and meta-analysis. J Clin Sleep Med. (2021) 17:299–313. doi: 10.5664/jcsm.8930
3. Wang, Y, Shi, L, Que, J, Lu, Q, Liu, L, Lu, Z, et al. The impact of quarantine on mental health status among general population in China during the COVID-19 pandemic. Mol Psychiatry. (2021) 26:4813–22. doi: 10.1038/s41380-021-01019-y
4. Lanza, G, DelRosso, LM, and Ferri, R. Sleep and homeostatic control of plasticity. Handb Clin Neurol. (2022) 184:53–72. doi: 10.1016/B978-0-12-819410-2.00004-7
5. Lina, Q, Yinan, S, Lianhong, T, Yanshu, J, and Yongsheng, Y. Efficacy of electroacupuncture stimulating Shenmen (HT7), Baihui (GV20), Sanyinjiao (SP6) on spatial learning and memory deficits in rats with insomnia induced by para-chlorophenylalanine: a single acupoint combined acupoints. J Tradit Chin Med. (2023) 43:704–14. doi: 10.19852/j.cnki.jtcm.20230308.001
6. Dopheide, JA. Insomnia overview: epidemiology, pathophysiology, diagnosis and monitoring, and nonpharmacologic therapy. Am J Manag Care. (2020) 26:S76–84. doi: 10.37765/ajmc.2020.42769
7. Blane, D, Williams, C, Morrison, J, Wilson, A, and Mercer, S. Cognitive behavioural therapy: why primary care should have it all. Br J Gen Pract. (2013) 63:103–4. doi: 10.3399/bjgp13X663235
8. Weisberg, RB, and Magidson, JF. Integrating cognitive behavioral therapy into primary care settings. Cogn Behav Pract. (2014) 21:247–51. doi: 10.1016/j.cbpra.2014.04.002
9. Zhang, MM, Tan, X, Zheng, YB, Zeng, N, Li, Z, Horowitz, MA, et al. Incidence and risk factors of antidepressant withdrawal symptoms: a meta-analysis and systematic review. Mol Psychiatry. (2025) 30:1758–69. doi: 10.1038/s41380-024-02782-4
10. Kakazu, VA, Assis, M, Bacelar, A, Bezerra, AG, Ciutti, GLR, Conway, SG, et al. Insomnia and its treatments—trend analysis and publication profile of randomized clinical trials. npj Biol Timing. Sleep. (2024) 1:14. doi: 10.1038/s44323-024-00014-0
11. Sekula, P, Del Greco, MF, Pattaro, C, and Köttgen, A. Mendelian Randomization as an Approach to Assess Causality Using Observational Data. J Am Soc Nephrol. (2016) 27:3253–65. doi: 10.1681/ASN.2016010098
12. Georgakis, MK, and Gill, D. Mendelian Randomization Studies in Stroke: Exploration of Risk Factors and Drug Targets With Human Genetic Data. Stroke. (2021) 52:2992–3003. doi: 10.1161/STROKEAHA.120.032617, Erratum in: Stroke. 2021 Nov;52(11):e753. doi: 10.1161/STR.0000000000000392
13. Larsson, SC, Butterworth, AS, and Burgess, S. Mendelian randomization for cardiovascular diseases: principles and applications. Eur Heart J. 2023;44:4913–4924. doi: 10.1093/eurheartj/ehad736
14. Zhu, T, Shen, D, Cai, X, Jin, Y, Tu, H, Wang, S, et al. The causal relationship between gut microbiota and preterm birth: a two-sample Mendelian randomization study. J Matern Fetal Neonatal Med. (2025) 38:2432528. doi: 10.1080/14767058.2024.2432528,
15. Grant, AJ, and Burgess, S. Pleiotropy robust methods for multivariable Mendelian randomization. Stat Med. 2021;40:5813–5830. doi: 10.1002/sim.9156
16. Larsson, SC, and Markus, HS. Genetic Liability to Insomnia and Cardiovascular Disease Risk. Circulation. (2019) 140:796–8. doi: 10.1161/CIRCULATIONAHA.119.041830,
17. Yuan, S, Mason, AM, Burgess, S, and Larsson, SC. Genetic liability to insomnia in relation to cardiovascular diseases: a Mendelian randomisation study. Eur J Epidemiol. 2021;36:393–400. doi: 10.1007/s10654-021-00737-5
18. Zhang, X, Sun, Y, Ye, S, Huang, Q, Zheng, R, Li, Z, et al.. Associations between insomnia and cardiovascular diseases: a meta-review and meta-analysis of observational and Mendelian randomization studies. J Clin Sleep Med. 2024;20:1975–1984. doi: 10.5664/jcsm.11326
19. Zhang, Z, Li, L, Zhang, Z, Hu, Z, Xiong, Y, Zhou, L, et al. Associations of 50 modifiable risk factors with atrial fibrillation using Mendelian randomization analysis. Eur J Clin Invest. (2024) 54:e14194. doi: 10.1111/eci.14194,
20. Arora, N, Bhatta, L, Skarpsno, ES, Dalen, H, Åsvold, BO, Brumpton, BM, et al. Investigating the causal interplay between sleep traits and risk of acute myocardial infarction: a Mendelian randomization study. BMC Med. 2023;21:385. doi: 10.1186/s12916-023-03078-0
21. Sivertsen, B, Lallukka, T, Salo, P, Pallesen, S, Hysing, M, Krokstad, S, et al. Insomnia as a risk factor for ill health: results from the large population-based prospective HUNT Study in Norway. J Sleep Res. (2014) 23:124–32. doi: 10.1111/jsr.12102,
22. Knutson, KL, and Van Cauter, E. Associations between sleep loss and increased risk of obesity and diabetes. Ann N Y Acad Sci. 2008;1129:287–304. doi: 10.1196/annals.1417.033
23. Balbo, M, Leproult, R, and Van Cauter, E. Impact of sleep and its disturbances on hypothalamo-pituitary-adrenal axis activity. Int J Endocrinol. 2010;2010:759234. doi: 10.1155/2010/759234
24. Said, MA, Verweij, N, and van der Harst, P. Associations of Combined Genetic and Lifestyle Risks With Incident Cardiovascular Disease and Diabetes in the UK Biobank Study. JAMA Cardiol. 2018;3:693–702. doi: 10.1001/jamacardio.2018.1717
25. Duan, D, Kim, LJ, Jun, JC, and Polotsky, VY. Connecting insufficient sleep and insomnia with metabolic dysfunction. Ann N Y Acad Sci. 2023;1519:94–117. doi: 10.1111/nyas.14926
26. Xie, J, Li, Y, Zhang, Y, Vgontzas, AN, Basta, M, Chen, B, et al. Sleep duration and metabolic syndrome: An updated systematic review and meta-analysis. Sleep Med Rev. (2021) 59:101451. Erratum in: Sleep Med Rev. 2023;68:101751. doi: 10.1016/j.smrv.2023.101751.
27. Xiuyun, W, Jiating, L, Minjun, X, Weidong, L, Qian, W, and Lizhen, L. Network Mendelian randomization study: exploring the causal pathway from insomnia to type 2 diabetes. BMJ Open Diabetes Res Care. 2022;10:e002510. doi: 10.1136/bmjdrc-2021-002510
28. Liu, J, Richmond, RC, Bowden, J, Barry, C, Dashti, HS, Daghlas, I, et al. Assessing the Causal Role of Sleep Traits on Glycated Hemoglobin: A Mendelian Randomization Study. Diabetes Care. (2022) 45:772–81. doi: 10.2337/dc21-0089
29. Liu, M, Yu, X, Shi, J, Su, J, Wei, M, and Zhu, Q. Establishing causal relationships between insomnia and gestational diabetes mellitus using Mendelian randomization. Heliyon. 2024;10:e33638. doi: 10.1016/j.heliyon.2024.e33638IF: 3.6
30. Knutson, KL, Spiegel, K, Penev, P, and Van Cauter, E. The metabolic consequences of sleep deprivation. Sleep Med Rev. 2007;11:163–78. doi: 10.1016/j.smrv.2007.01.002. ; PMCID: PMC1991337.
31. Patel, SR, Zhu, X, Storfer-Isser, A, Mehra, R, Jenny, NS, Tracy, R, et al. Sleep duration and biomarkers of inflammation. Sleep. 2009;32:200–4. doi: 10.1093/sleep/32.2.200
32. Hayes, BL, Vabistsevits, M, Martin, RM, Lawlor, DA, Richmond, RC, and Robinson, T. Establishing causal relationships between sleep and adiposity traits using Mendelian randomization. Obesity (Silver Spring). 2023;31:861–870. doi: 10.1002/oby.23668
33. Spiegel, K, Tasali, E, Penev, P, and Van Cauter, E. Brief communication: Sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann Intern Med. (2004) 141:846–50. doi: 10.7326/0003-4819-141-11-200412070-00008IF: 15.2 Q1,
34. Khandaker, GM, Cousins, L, Deakin, J, Lennox, BR, Yolken, R, and Jones, PB. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry. 2015;2:258–270. doi: 10.1016/S2215-0366(14)00122-9IF: 24.8 Q1
35. Vgontzas, AN, Bixler, EO, Lin, HM, Prolo, P, Mastorakos, G, Vela-Bueno, A, et al. Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications. J Clin Endocrinol Metab. (2001) 86:3787–94. doi: 10.1210/jcem.86.8.7778,
36. Fraser, R, Ingram, MC, Anderson, NH, Morrison, C, Davies, E, and Connell, JM. Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Hypertension. (1999) 33:1364–8. doi: 10.1161/01.hyp.33.6.1364,
37. Guan, Z, Vgontzas, AN, Bixler, EO, and Fang, J. Sleep is increased by weight gain and decreased by weight loss in mice. Sleep. 2008;31:627–33. doi: 10.1093/sleep/31.5.627
38. Arab, A, Karimi, E, Garaulet, M, and Scheer, FAJL. Dietary patterns and insomnia symptoms: A systematic review and meta-analysis. Sleep Med Rev. 2024;75:101936. doi: 10.1016/j.smrv.2024.101936
39. Tan, XJ, Jiao, GP, Ren, YJ, Gao, XR, Ding, Y, Wang, XR, et al. Relationship between smoking and dyslipidemia in western Chinese elderly males. J Clin Lab Anal. 2008;22:159–63. doi: 10.1002/jcla.20235
40. Wong, WS, and Fielding, R. Prevalence of insomnia among Chinese adults in Hong Kong: a population-based study. J Sleep Res. (2011) 20:117–26. doi: 10.1111/j.1365-2869.2010.00822.xIF: 3.9 Q1,
41. Lee, K, and Lim, CY. Mendelian Randomization Analysis in Observational Epidemiology. J Lipid Atheroscler. 2019;8:67–77. doi: 10.12997/jla.2019.8.2.67
42. Luo, J, Tu, L, Zhou, C, Li, G, Shi, L, and Hu, S. SGLT2 inhibition, circulating proteins, and insomnia: A mendelian randomization study. Sleep Med. (2024) 119:480–7. doi: 10.1016/j.sleep.2024.05.036,
43. Haack, M, Simpson, N, Sethna, N, Kaur, S, and Mullington, J. Sleep deficiency and chronic pain: potential underlying mechanisms and clinical implications. Neuropsychopharmacology. 2020;45:205–216. doi: 10.1038/s41386-019-0439-z
44. Rosenfalck, AM, Almdal, T, Viggers, L, Madsbad, S, and Hilsted, J. A low-fat diet improves peripheral insulin sensitivity in patients with Type 1 diabetes. Diabet Med. (2006) 23:384–92. doi: 10.1111/j.1464-5491.2005.01810.x,
45. Brook, DW, Rubenstone, E, Zhang, C, and Brook, JS. Trajectories of cigarette smoking in adulthood predict insomnia among women in late mid-life. Sleep Med. 2012;13:1130–7. doi: 10.1016/j.sleep.2012.05.008
46. Grandner, MA, Jackson, N, Gerstner, JR, and Knutson, KL. Dietary nutrients associated with short and long sleep duration. Data from a nationally representative sample. Appetite. 2013;64:71–80. doi: 10.1016/j.appet.2013.01.004
47. Ni, J, Zhou, W, Cen, H, Chen, G, Huang, J, Yin, K, et al. Evidence for causal effects of sleep disturbances on risk for osteoarthritis: a univariable and multivariable Mendelian randomization study. Osteoarthritis Cartilage. (2022) 30:443–50. doi: 10.1016/j.joca.2021.11.021IF: 9.0 Q1,
48. Shu, P, Ji, L, Ping, Z, Sun, Z, and Liu, W. Association of insomnia and daytime sleepiness with low back pain: A bidirectional mendelian randomization analysis. Front Genet. 2022;13:938334. doi: 10.3389/fgene.2022.938334
49. Liu, M, McCurry, SM, Belza, B, Dobra, A, Buchanan, DT, Vitiello, MV, et al. Effects of Osteoarthritis Pain and Concurrent Insomnia and Depression on Health Care Use in a Primary Care Population of Older Adults. Arthritis Care Res (Hoboken). 2019;71:748–757. doi: 10.1002/acr.23695
50. Irwin, MR, Olmstead, R, and Carroll, JE. Sleep Disturbance, Sleep Duration, and Inflammation: A Systematic Review and Meta-Analysis of Cohort Studies and Experimental Sleep Deprivation. Biol Psychiatry. 2016;80:40–52. doi: 10.1016/j.biopsych.2015.05.014IF: 9.0 Q1
51. Wu, J, Li, Q, Deng, J, Zhao, JJ, and Yu, QH. Association between IL-33 and other inflammatory factors in patients with rheumatoid arthritis and in fibroblast-like synoviocytes in vitro. Exp Ther Med. 2021;21:161. doi: 10.3892/etm.2020.9592.
52. Zhou, M, Yang, S, Guo, Y, Wang, D, Qiu, W, Wang, B, et al. Shift work and the risk of knee osteoarthritis among Chinese workers: a retrospective cohort study. Scand J Work Environ Health. (2020) 46:152–60. doi: 10.5271/sjweh.3861,
53. Cohen, J, Pignanelli, C, and Burr, J. The Effect of Body Position on Measures of Arterial Stiffness in Humans. J Vasc Res. (2020) 57:143–51. doi: 10.1159/000506351,
54. Gao, RC, Sang, N, Jia, CZ, Zhang, MY, Li, BH, and Wei, M. Association Between Sleep Traits and Rheumatoid Arthritis: A Mendelian Randomization Study. Front Public Health. 2022;10:940161. doi: 10.3389/fpubh.2022.940161
55. Yang, LN, Chen, K, Yin, XP, Liu, D, and Zhu, LQ. The Comprehensive Neural Mechanism of Oxytocin in Analgesia. Curr Neuropharmacol. 2022;20:147–157. doi: 10.2174/1570159X19666210826142107
56. Broberg, M, Karjalainen, J, and FinnGen; Ollila HM,. Mendelian randomization highlights insomnia as a risk factor for pain diagnoses. Sleep. 2021;44:zsab025. doi: 10.1093/sleep/zsab025
57. Yao, C, Zhang, Y, Lu, P, Xiao, B, Sun, P, Tao, J, et al. Exploring the bidirectional relationship between pain and mental disorders: a comprehensive Mendelian randomization study. J Headache Pain. 2023;24:82. doi: 10.1186/s10194-023-01612-2
58. Chu, S, Wu, Z, Wu, Z, Wu, J, and Qian, Y. Association Between Insomnia and Migraine Risk: A Case-Control and Bidirectional Mendelian Randomization Study. Pharmgenomics Pers Med. 2021;14:971–976. doi: 10.2147/PGPM.S305780
59. Finan, PH, Goodin, BR, and Smith, MT. The association of sleep and pain: an update and a path forward. J Pain. (2013) 14:1539–52. doi: 10.1016/j.jpain.2013.08.007
60. Imeri, L, and Opp, MR. How (and why) the immune system makes us sleep. Nat Rev Neurosci. (2009) 10:199–210. doi: 10.1038/nrn2576
61. Smith, MT, Edwards, RR, McCann, UD, and Haythornthwaite, JA. The effects of sleep deprivation on pain inhibition and spontaneous pain in women. Sleep. (2007) 30:494–505. doi: 10.1093/sleep/30.4.494
62. Salwen, JK, Smith, MT, and Finan, PH. Mid-treatment sleep duration predicts clinically meaningful outcomes in CBT-I for chronic pain. Pain. (2022) 163:1589–97. doi: 10.1097/j.pain.0000000000002556
63. Russo, EB, and Hohmann, AG. Role of cannabinoids in pain management In: TR Deer, et al., editors. Comprehensive Treatment of Chronic Pain by Medical, Interventional, and Integrative Approaches : Springer (2013). 181–97. doi: 10.1007/978-1-4614-1569-3_20
64. Ator, NA, and Griffiths, RR. Selectivity in GABAA receptor ligands: a review of the pharmacology and clinical effects of zolpidem, eszopiclone, and zaleplon. CNS Drug Rev. (2007) 13:520–39. doi: 10.1111/j.1527-3458.2007.00029.x
65. Finnerup, NB, Attal, N, Haroutounian, S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. (2015) 14:162–73. doi: 10.1016/S1474-4422(14)70251-0
66. Hansen, MV, Halladin, NL, Rosenberg, J, et al. Melatonin for pre- and postoperative anxiety in adults. Cochrane Database Syst Rev. (2015) CD009861. doi: 10.1002/14651858.CD009861.pub2
67. Baglioni, C, Battagliese, G, Feige, B, et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord. (2011) 135:10–9. doi: 10.1016/j.jad.2011.01.011
68. Alvaro, CG, Roberts, RM, and Harris, JK. A systematic review assessing bidirectionality between sleep disturbances, anxiety, and depression. Sleep. (2013) 36:1059–68. doi: 10.5665/sleep.2818
69. Li, L, Wu, C, Gan, Y, Qu, X, and Lu, Z. Insomnia and the risk of depression: a meta-analysis of prospective cohort studies. BMC Psychiatry. (2016) 16:375. doi: 10.1186/s12888-016-1075-3
70. Zhou, F, Li, S, and Xu, H. Insomnia, sleep duration, and risk of anxiety: A two-sample Mendelian randomization study. J Psychiatr Res. (2022) 155:219–25. doi: 10.1016/j.jpsychires.2022.08.012,
71. Huang, P, Zou, Y, Zhang, X, Ye, X, Wang, Y, and Yu, R. The Causal Effects of Insomnia on Bipolar Disorder, Depression, and Schizophrenia: A Two-Sample Mendelian Randomization Study. Front Genet. 2021;12:763259. doi: 10.3389/fgene.2021.763259
72. Gao, X, Meng, LX, Ma, KL, Liang, J, Wang, H, Gao, Q, et al. The bidirectional causal relationships of insomnia with five major psychiatric disorders: A Mendelian randomization study. Eur Psychiatry. (2019) 60:79–85. doi: 10.1016/j.eurpsy.2019.05.004,
73. Wohleb, ES, Franklin, T, Iwata, M, and Duman, RS. Integrating neuroimmune systems in the neurobiology of depression. Nat Rev Neurosci. (2016) 17:497–511. doi: 10.1038/nrn.2016.69,
74. Chu, T, Guo, Z, Zhang, W, Wang, L, Lv, S, Guo, W, et al. Mechanism of volatile oil from Yueju Pill in anti-depression by regulating AGE/PI3K/Akt pathway to inhibit inflammation. China Journal of Chinese Materia Medica. (2025) 50:3147–58. doi: 10.19540/j.cnki.cjcmm.20250313.305
75. Guo, C, Harshfield, EL, and Markus, HS. Sleep Characteristics and Risk of Stroke and ementia:An Observational and Mendelian Randomization Study. Neurology. 2024;102:e209141. doi: 10.1212/WNL.0000000000209141
76. GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science. (2020) 369:1318–30. doi: 10.1126/science.aaz1776
77. Anderson, EL, Richmond, RC, Jones, SE, Hemani, G, Wade, KH, Dashti, HS, et al. Is disrupted sleep a risk factor for Alzheimer’s disease? Evidence from a two-sample Mendelian randomization analysis. Int J Epidemiol. 2021;50:817–828. doi: 10.1093/ije/dyaa183
78. Liu, C, Wang, C, Jiang, J, Bo, Y, Nan, L, and Zhang, Y,, et al.Role of metabolic characteristics in the co-occurrence of insomnia, Alzheimer’s disease, and Parkinson’s disease: a Mendelian randomization study. Front Aging Neurosci. 2025;16:1436171. doi: 10.3389/fnagi.2024.1436171
79. He, F, Yang, F, Tang, C, Chen, D, Xiong, J, Zou, Y, et al. Association between sleep traits and risk of colorectal cancer: a bidirectional Mendelian randomization study. J Gastrointest Oncol. 2024;15:1556–1567. doi: 10.21037/jgo-24-11
80. Yuan, S, Mason, AM, Titova, OE, Vithayathil, M, Kar, S, Chen, J, et al. Morning chronotype and digestive tract cancers: Mendelian randomization study. Int J Cancer. 2023;152:697–704. doi: 10.1002/ijc.34284
81. Huo, Z, Ge, F, Li, C, Cheng, H, Lu, Y, Wang, R, et al. Genetically predicted insomnia and lung cancer risk: a Mendelian randomization study. Sleep Med. (2021) 87:183–90. doi: 10.1016/j.sleep.2021.06.044,
82. Wang, H, Reid, BM, Richmond, RC, Lane, JM, Saxena, R, Gonzalez, BD, et al. Impact of insomnia on ovarian cancer risk and survival: a Mendelian randomization study. EBioMedicine. 2024;104:105175. doi: 10.1016/j.ebiom.2024.105175
83. Du, L, Wang, B, Wen, J, and Zhang, N. No causal association between insomnia and bladder cancer: a bidirectional two-sample Mendelian randomization study. Eur J Med Res. 2024;29:316. doi: 10.1186/s40001-024-01920-6
84. Yu, H, Pardoll, D, and Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9:798–809. doi: 10.1038/nrc2734
85. Hayes, BL, Fleming, L, Mahmoud, O, Martin, RM, Lawlor, DA, and Robinson, T. The impact of sleep on breast cancer-specific mortality: a Mendelian randomisation study. BMC Cancer. 2025;25:357. doi: 10.1186/s12885-025-13681-4
86. Hoffman, AE, Zheng, T, Ba, Y, et al. The circadian gene PER2 plays an important role in tumor suppression through regulating cell proliferation and DNA damage. Carcinogenesis. (2008) 29:379–86. doi: 10.1093/carcin/bgm276
87. Blask, DE, Dauchy, RT, Dauchy, EM, et al. Light exposure at night disrupts host/cancer circadian regulatory dynamics: impact on the melatonin signal, DNA damage and tumor growth. Int J Mol Sci. (2022) 23:1394. doi: 10.3390/ijms23031394
89. Liu, R, Wang, X, Chen, GY, et al. IL-6/STAT3 pathway links insomnia to cancer-associated inflammation: experimental and Mendelian randomization evidence. J Immunother Cancer. (2023) 11:e006123. doi: 10.1136/jitc-2022-006123
90. Yang, X, Wang, J, and Wang, H. Association between sleep traits and primary liver cancer: A Mendelian randomization analysis. Eur J Clin Invest. (2023) 53:e14002. doi: 10.1111/eci.14002,
91. Bao, W, Qi, L, Bao, Y, Wang, S, and Li, W. Alleviating insomnia should decrease the risk of irritable bowel syndrome: Evidence from Mendelian randomization. Front Pharmacol. 2022;13:900788. doi: 10.3389/fphar.2022.900788
92. Zha, LF, Dong, JT, Wang, JL, Chen, QW, Wu, JF, Zhou, YC, et al. Effects of Insomnia on Peptic Ulcer Disease Using Mendelian Randomization. Oxid Med Cell Longev. 2021;2021:2216314. doi: 10.1155/2021/2216314
93. Zha, LF, Dong, JT, Wang, JL, Chen, QW, Wu, JF, Zhou, YC, et al. Effects of Insomnia on Peptic Ulcer Disease Using Mendelian Randomization. Oxid Med Cell Longev. 2021;2021:2216314. doi: 10.1155/2021/2216314
94. Wang, X, Wang, C, Liu, K, Wan, Q, Wu, W, and Liu, C. Association between sleep-related phenotypes and gut microbiota: a two-sample bidirectional Mendelian randomization study. Front Microbiol. (2024) 15:1341643. doi: 10.3389/fmicb.2024.1341643
95. Li, Y, Deng, Q, and Liu, Z. The relationship between gut microbiota and insomnia: a bi-directional two-sample Mendelian randomization research. Front Cell Infect Microbiol. 2023;13:1296417. doi: 10.3389/fcimb.2023.1296417
96. Wang, Q, Gao, T, Zhang, W, et al. Causal relationship between the gut microbiota and insomnia: a two-sample Mendelian randomization study[J]. Frontiers in Cellular and Infection Microbiology. (2024) 14:1279218. doi: 10.3389/fcimb.2024.1279218
97. Smith, RP, Easson, C, Lyle, SM, et al. Gut microbiome diversity is associated with sleep physiology in humans. PLoS ONE. (2019) 14:e0222394. doi: 10.1371/journal.pone.0222394
98. Valles-Colomer, M, Falony, G, Darzi, Y, Tigchelaar, EF, Wang, J, Tito, RY, et al. The neuroactive potential of the human gut microbiota in quality of life and depression. Nat Microbiol. (2019) 4:623–32. doi: 10.1038/s41564-018-0337-x
99. Xie, F, Feng, Z, and Xu, B. Metabolic Characteristics of Gut Microbiota and Insomnia: Evidence from a Mendelian Randomization Analysis. Nutrients. 2024;16:2943. doi: 10.3390/nu16172943.
100. Li, Y, Li, T, Zhang, Y, Wang, Y, Wu, G, and Tan, Y. Microbial metabolites in the gut-brain axis: their impact on depression pathophysiology and treatment. Neuroscience. (2025) 593:1–7. doi: 10.1016/j.neuroscience.2025.12.002,
101. Nguyen, PT, Coetzee, SG, Silacheva, I, and Hazelett, DJ. Genome wide association studies are enriched for interacting genes. Res Sq [Preprint]. 2024:rs.3.rs–5189487. doi: 10.21203/rs.3.rs-5189487/v2. Update in: BioData Min. 2025;18(1):3. doi: 10.1186/s13040-024-00421-w
102. Kurilshikov, A, Medina-Gomez, C, Bacigalupe, R, Radjabzadeh, D, Wang, J, Demirkan, A, et al. Large-scale association analyses identify host factors influencing human gut microbiome composition. Nat Genet. (2021) 53:156–65. doi: 10.1038/s41588-020-00763-1
103. Zhang, S, Liu, SX, Wu, QJ, Wang, ZH, Liu, H, Dong, C, et al. Association of dietary fiber with subjective sleep quality in hemodialysis patients: a cross-sectional study in China. Ann Med. 2023;55:558–571. doi: 10.1080/07853890.2023.2176541
104. He, D, Meng, P, Li, C, Jia, Y, Wen, Y, Pan, C, et al. Association between telomere length and insomnia: A mendelian randomization and colocalization study. Sleep Med. (2022) 100:304–10. doi: 10.1016/j.sleep.2022.09.002,
105. Lansdorp, PM. Sex differences in telomere length, lifespan, and embryonic dyskerin levels. Aging Cell. 2022;21:e13614. doi: 10.1111/acel.13614
106. Bayne, S, Li, H, Jones, ME, Pinto, AR, van Sinderen, M, Drummond, A, et al. Estrogen deficiency reversibly induces telomere shortening in mouse granulosa cells and ovarian aging in vivo. Protein Cell. 2011;2:333–46. doi: 10.1007/s13238-011-1033-2
107. Yang, Q, Borges, MC, Sanderson, E, Magnus, MC, Kilpi, F, and Collings, PJ,, et al. Associations between insomnia and pregnancy and perinatal outcomes: Evidence from mendelian randomization and multivariable regression analyses. PLoS Md. 2022;19:e1004090. doi: 10.1371/journal.pmed.1004090
108. Yang, Q, Borges, MC, Sanderson, E, Magnus, MC, Kilpi, F, Collings, PJ, et al. Associations between insomnia and pregnancy and perinatal outcomes: Evidence from mendelian randomization and multivariable regression analyses. PLoS Med. 2022;19:e1004090. doi: 10.1371/journal.pmed.1004090
109. Bai, Y, Zeng, Z, Li, X, and Gong, W. The predictive effect of mid-pregnancy sleep disorders on perinatal depression within women with or without depression in early pregnancy: A prospective cohort study. J Affect Disord. (2024) 345:18–23. doi: 10.1016/j.jad.2023.10.103,
110. Ghimire, U, Papabathini, SS, Kawuki, J, Obore, N, and Musa, TH. Depression during pregnancy and the risk of low birth weight, preterm birth and intrauterine growth restriction- an updated meta-analysis. Early Hum Dev. (2021) 152:105243. doi: 10.1016/j.earlhumdev.2020.105243,
111. Ference, BA, Holmes, MV, and Smith, GD. Using Mendelian randomization to improve the design of randomized trials. Cold Spring Harbor Perspectives in Medicine. (2021) 11:a040980. doi: 10.1101/cshperspect.a040980
Keywords: causal inference, insomnia, Mendelian randomization, review, risk factors
Citation: Hou X, Wei Y, Wang Y and Wang L (2026) Mendelian randomization studies on the causal relationship between insomnia and disease. Front. Med. 12:1709983. doi: 10.3389/fmed.2025.1709983
Edited by:
Vincenzo Piccolo, University of Naples Federico II, ItalyReviewed by:
Shinsuke Hidese, Teikyo University, JapanVahid Rashedi, University of Social Welfare and Rehabilitation Sciences, Iran
Copyright © 2026 Hou, Wei, Wang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yingjun Wei, MjIwNjQ2MTE5NEBxcS5jb20=